The goals of this study are as follows: 1. to confirm the safe dosing of ropivacaine for the erector spinae plane block 2. develop a pharmacokinetic profile of the erector spinae plane block, which will help demonstrate how quickly and how closely toxic levels are reached when a routine dose of ropivacaine is given for this nerve block 3. assess numbness created by the erector spinae block when routine doses are administered
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
0.25% ropivacaine administered through a nerve catheter
0.2% ropivacaine administered through a nerve catheter
Virginia Commonwealth University
Richmond, Virginia, United States
Cmax
The maximum concentration of serum ropivacaine after pre-determined dose is delivered through the ESP nerve catheter
Time frame: 28 hours
Tmax
The time elapsed from initial ropivacaine administration to Cmax
Time frame: 28 hours
Area of analgesia
The area of numbness experienced in the chest wall; measured using a pinprick test and documented on a cartoon map showing a chest wall and dermatomal borders
Time frame: 4 hours
Duration of analgesia
The duration of numbness to the chest wall; start time will be when the local anesthetic bolus is given, and end time will be when the participant reports the resolution of chest wall numbness
Time frame: 4 hours
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.